nach oben

Erschienen in:

28.04.2017

Hypertonic Saline as a Useful Tool for Sputum Induction and Pathogen Detection in Cystic Fibrosis

verfasst von: Adriana Carolina Marques Ferreira, Fernando Augusto Lima Marson, Milena Antonelli Cohen, Carmen Silvia Bertuzzo, Carlos Emilio Levy, Antonio Fernando Ribeiro, Jose Dirceu Ribeiro

Erschienen in: Lung | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to compare the qualitative and semi-quantitative detection of pathogens in the airway secretions of patients with cystic fibrosis (CF) and the sputum induction capacity before and after inhalation of 7% hypertonic saline solution (HSS).

Methods

The study enrolled 64 patients with CF. Airway secretions were collected from all enrolled patients with CF before and after inhalation of 7% HSS, and the samples were screened for pathogens.

Results

Inhalation of 7% HSS increased the probability of producing sputum from 36 to 52% (p = 0.002) in children with CF. The effect was most in children under 11 years. Inhalation of 7% HSS improved qualitative pathogen identification (p = 0.008). Inhalation of 7% HSS increased the mucoid Pseudomonas aeruginosa (p = 0.002) and non-mucoid P. aeruginosa in the semi-quantitative analysis (p = 0.035). Four new pathogens (Aspergillus fumigatus, Achromobacter xylosoxidans, Ochrobactrum anthropi, and Elizabethkingia meningoseptica) were identified in the sputum samples collected from the airways of patients with CF following 7% HSS.

Conclusions

Inhalation of 7% HSS increased sputum production and pathogen identification in children with CF. The inhalation of 7% HSS was feasible and should be implemented for routine pathogen detection in the airways of patients with CF, particularly in those patients who do not produce sputum.

Nur mit Berechtigung zugänglich

Foundation CF (2015) Cystic fibrosis foundation patient registry. Annual data report

Elborn JS (2016) Cystic fibrosis. Lancet 388(10059):2519–2531. doi:10.1016/S0140-6736(16)00576-6 CrossRefPubMed

Sosnay PR, Raraigh KS, Gibson RL (2016) Molecular genetics of cystic fibrosis transmembrane conductance regulator: genotype and phenotype. Pediatr Clin N Am 63(4):585–598. doi:10.1016/j.pcl.2016.04.002 CrossRef

Egan ME (2016) Genetics of cystic fibrosis: clinical implications. Clin Chest Med 37(1):9–16. doi:10.1016/j.ccm.2015.11.002 CrossRefPubMed

Brennan ML, Schrijver I (2016) Cystic fibrosis: a review of associated phenotypes, use of molecular diagnostic approaches, genetic characteristics, progress, and dilemmas. J Mol Diagn 18(1):3–14. doi:10.1016/j.jmoldx.2015.06.010 CrossRefPubMed

Marson FAL, Bertuzzo CS, Hortencio TD, Ribeiro JD, Bonadia LC, Ribeiro AF (2012) The ACE gene D/I polymorphism as a modulator of severity of cystic fibrosis. BMC Pulm Med 12:41. doi:10.1186/1471-2466-12-41 CrossRefPubMedPubMedCentral

Marson FAL, Bertuzzo CS, Ribeiro AF, Ribeiro JD (2012) Polymorphisms in ADRB2 gene can modulate the response to bronchodilators and the severity of cystic fibrosis. BMC Pulm Med 12(1):50. doi:10.1186/1471-2466-12-50 CrossRefPubMedPubMedCentral

Marson FAL, Bertuzzo CS, Secolin R, Ribeiro AF, Ribeiro JD (2013) Genetic interaction of GSH metabolic pathway genes in cystic fibrosis. BMC Med Genet 14:60. doi:10.1186/1471-2350-14-60 CrossRefPubMedCentral

Marson FAL, Bertuzzo CS, Ribeiro AF, Ribeiro JD (2014) Polymorphisms in the glutathione pathway modulate cystic fibrosis severity: a cross-sectional study. BMC Med Genet 15:27. doi:10.1186/1471-2350-15-27 CrossRefPubMedPubMedCentral

10.

Furlan LL, Marson FAL, Ribeiro JD, Bertuzzo CS, Salomão Junior JB, Souza DR (2016) IL8 gene as modifier of cystic fibrosis: unraveling the factors which influence clinical variability. Hum Genet 135(8):881–894. doi:10.1007/s00439-016-1684-4 CrossRefPubMed

11.

De Boeck K, Alifier M, Vandeputte S (2000) Sputum induction in young cystic fibrosis patients. Eur Respir J 16:91–94CrossRefPubMed

12.

Gibson RL, Burns JL, Ramsey BW (2003) Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168:918–951CrossRefPubMed

13.

Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT, National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group (2006) A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354(3):229–240. doi:10.1056/NEJMoa043900 CrossRefPubMed

14.

Subbarao P, Balkovec S, Solomon M, Ratjen F (2007) Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatr Pulmonol 42:471–476. doi:10.1002/ppul.20603 CrossRefPubMed

15.

Stoltz DA, Meyerholz DK, Welsh MJ (2015) Origins of cystic fibrosis lung disease. N Engl J Med 372(4):351–362. doi:10.1056/NEJMra1300109 CrossRefPubMedPubMedCentral

16.

Seidler D, Griffin M, Nymon A, Koeppen K, Ashare A (2016) Throat swabs and sputum culture as predictors of P. aeruginosa or S. aureus lung colonization in adult cystic fibrosis patients. PLoS ONE 11(10):e0164232. doi:10.1371/journal.pone.0164232 CrossRefPubMedPubMedCentral

17.

Burns JL, Rolain JM (2014) Culture-based diagnostic microbiology in cystic fibrosis: Can we simplify the complexity? J Cyst Fibros 13(1):1–9. doi:10.1016/j.jcf.2013.09.004 CrossRefPubMed

18.

Zemanick ET, Wagner BD, Robertson CE, Stevens MJ, Szefler SJ, Accurso FJ, Sagel SD, Harris JK (2015) Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods. Ann Am Thorac Soc 12(2):221–229. doi:10.1513/AnnalsATS.201407-310OC CrossRefPubMedPubMedCentral

19.

Hoppe JE, Towler EE, Wagner BD, Accurso FJ, Sagel SD, Zemanick ET (2015) Sputum induction improves detection of pathogens in children with cystic fibrosis. Pediatr Pulmonol 50(7):638–646. doi:10.1002/ppul.23150 CrossRefPubMedPubMedCentral

20.

Kussek P, Rosario-Filho NA, Cat M (2006) Bronchial hyperresponsiveness to hypertonic saline challenge in children and adolescents. J Bras Pneumol 32(2):195–201CrossRefPubMed

21.

Henke MO, Ratjen F (2007) Mucolytics in cystic fibrosis. Paeditr Pulmonol Rev 8(1):24–29. doi:10.1016/j.prrv.2007.02.009

22.

Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, Lubsch L, Hazle L, Sabadosa K, Marshall B, Pulmonary Clinical Practice Guidelines Committee (2013) Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 187(7):680–689. doi:10.1164/rccm.201207-1160OE CrossRefPubMed

23.

Elkins MR, Bye PT (2011) Mechanisms and applications of hypertonic saline. J R Soc Med 104(1):S2–S5. doi:10.1258/jrsm.2011.s11101 CrossRefPubMedPubMedCentral

24.

Maiya S, Desai M, Baruah A, Weller P, Clarke JR, Gray J (2004) Cough plate versus cough swab in patients with cystic fibrosis; a pilot study. Arch Dis Child 89:577–579CrossRefPubMedPubMedCentral

25.

Ho SA, Ball R, Morrison LJ, Brownlee KG, Conway SP (2004) Clinical value of obtaining sputum and cough swab samples following inhaled hypertonic saline in children with cystic fibrosis. Pediatr Pulmonol 38:82–87CrossRefPubMed

26.

Proesmans M, Balinska-Miskiewicz W, Dupont L, Bossuyt X, Verhaegen J, Høiby N, de Boeck K (2006) Evaluating the “Leeds criteria” for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur Respir J 27(5):937–943PubMed

27.

Suri R, Marshall LJ, Wallis C, Metcalfe C, Shute JK, Bush A (2003) Safety and use of sputum induction in children with cystic fibrosis. Pediatr Pulmonol 35:309–313CrossRefPubMed

28.

Wark P, McDonald VM (2009) Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. doi:10.1002/14651858.CD001506.pub3 PubMed

29.

Rosenfeld M, Ratjen F, Brumback L, Daniel S, Rowbotham R, McNamara S, Johnson R, Kronmal R, Davis SD, ISIS Study Group (2012) Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA 307(21):2269–2277. doi:10.1001/jama.2012.5214 CrossRefPubMedPubMedCentral

30.

Dean AG, Sullivan KM, Soe MM (2013) OpenEpi. Open source epidemiologic statistics for public health, Versão. www.OpenEpi.com. Updated 2013/04/06, accessed 2013/07/04

31.

Sly PD, Gangell CL, Chen L, Ware RS, Ranganathan S, Mott LS, Murray CP, Stick SM, AREST CF Investigators (2013) Risk factors for bronchiectasis in children with cystic fibrosis. N Engl J Med 368(21):1963–1970. doi:10.1056/NEJMoa1301725 CrossRefPubMed

32.

Ciofu O, Johansen HK, Aanaes K, Wassermann T, Alhede M, von Buchwald C, Høiby N (2013) P. aeruginosa in the paranasal sinuses and transplanted lungs have similar adaptive mutations as isolates from chronically infected CF lungs. J Cyst Fibros 12(6):729–736. doi:10.1016/j.jcf.2013.02.004 CrossRefPubMed

33.

Henig NR, Tonelli MR, Pier MV, Burns JL, Aitken ML (2001) Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax 56(4):306–311CrossRefPubMedPubMedCentral

34.

Robinson M, Hemming AL, Regnis JA, Wong AG, Bailey DL, Bautovich GJ, King M, Bye PT (1997) Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 52(10):900–903CrossRefPubMedPubMedCentral

35.

Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC (2006) Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 354(3):241–250. doi:10.1056/NEJMoa043891 CrossRefPubMed

36.

Rosenfeld M, Davis S, Brumback L, Daniel S, Rowbotham R, Johnson R, McNamara S, Jensen R, Barlow C, Ratjen F (2011) Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence and safety. Pediatr Pulmonol 46:666–671. doi:10.1002/ppul.21425 CrossRefPubMedPubMedCentral

Titel: Hypertonic Saline as a Useful Tool for Sputum Induction and Pathogen Detection in Cystic Fibrosis
verfasst von: Adriana Carolina Marques Ferreira
Fernando Augusto Lima Marson
Milena Antonelli Cohen
Carmen Silvia Bertuzzo
Carlos Emilio Levy
Antonio Fernando Ribeiro
Jose Dirceu Ribeiro
Publikationsdatum: 28.04.2017
Verlag: Springer US
Erschienen in: Lung / Ausgabe 4/2017
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-017-0008-3

Predictive Value of Mean Platelet Volume for Pulmonary Embolism Recurrence

Total IgM and Anti-Phosphatidylcholine IgM Antibody Secretion Continue After Clearance of Mycobacterium bovis Bacillus Calmette-Guerin Pleural Infection

Histological Diagnoses of Military Personnel Undergoing Lung Biopsy After Deployment to Southwest Asia

Deep Benign Fibrous Histiocytoma of the Anterior Mediastinum Mimicking Malignancy

Extraskeletal Osteosarcoma Arising from the Pleura

Increased Soluble VCAM-1 and Normal P-Selectin in Cystic Fibrosis: a Cross-Sectional Study

Open Access

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

ctDNA erkennt minimale Resterkrankung beim Melanom

25.04.2025
Tumormarker
Nachrichten

Die Diagnose einer minimalen Resterkrankung mithilfe zirkulierender Tumor-DNA könnte (ctDNA) auch das Management von Patientinnen und Patienten mit Melanomen im Stadium III bereichern, wie Ergebnisse einer Studie nahelegen – auch wenn die Methode noch nicht perfekt funktioniert.

Lipidtherapie im Praxisalltag: Noch viel Spielraum für Verbesserung

25.04.2025
DGK-Jahrestagung 2025
Kongressbericht

Wie steht es um die Behandlung von Dyslipidämien bei Risikopatienten mit atherosklerotischer Gefäßerkrankung in Deutschland? Eine Bestandsaufnahme dazu liefert das bei der DGK-Tagung 2025 vorgestellte Forschungsprojekt LipidSnapshot.

Lohnt sich die Karotis-Revaskularisation?

25.04.2025
Karotisstenose
Nachrichten

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Höhere Dosis von Dexamethason senkt Überlebenschancen

25.04.2025
Zerebrale Metastasen
Nachrichten

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Hypertonic Saline as a Useful Tool for Sputum Induction and Pathogen Detection in Cystic Fibrosis